Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Pluristem Therapeutics (PSTI) Potential Treatment of Radiation Exposure

Expands Testing of PLX Cells for the Treatment of Radiation Exposure

PSTI’s preliminary study indicated that the administration of PLX cells following radiation exposure resulted in a significant improvement in the repopulation of cells of the haematopoietic system within the animal’s bone marrow. The initial study conducted exposed NOD/SCID mice to a sub-lethal dose of radiation (350) and then injected them with PLX cells. Approximately 5 weeks after the injection of the cells, a significant recovery of the animal’s hematopoietic stem cells (HSCs), gave rise to all the blood cell types, including the cells of the immune system.

  • PSTI signed a collaborative agreement with the Hadassah University Medical Center to continue previously conducted animal study that indicates PLX cells are potentially effective in the treatment of radiation sickness.

The Bottom Line: According to PSTI, this early animal data collected from the initial study holds great promise to validate research and moving ahead with the next stage of testing. PSTI has found its PLX cells to be cytoprotective, which plays a role in protecting bone marrow cells from the adverse effects of radiation exposure. Exposure to high doses of ionizing radiation may be fatal, with no adequate efficient treatment, except for bone marrow transplantation in severe cases, which is a hazardous treatment by itself and in most cases is not easily available. The convincing initial data from the trial, using PLX cells to alleviate radiation damages, convinced PSTI to move ahead with additional testing.